Biophytis SA American Depositary Share (0.01 Euro)

BPTS

Capitalización de mercado USD 2.36 M

ADSs delisted from Nasdaq, which will result in meaningful savings ADSs transferred to OTC Pink market; Company will apply to trade on OTCQB market Biophytis remains listed on Euronext Growth Paris as its primary trading market PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / April 24, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in thedevelopment oftherapeutics for age-related diseases, today announced that on April 24, 2024, the Company received formal notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Nasdaq Hearings Panel (the "Panel") had determined to delist the Company's American Depositary Shares("ADSs") from The Nasdaq Capital Market based upon the Company's non-compliance with the stockholders' equity requirement set forth in Nasdaq Listing Rule 5550(b). As a result of the Panel's decision, Nasdaq will suspend trading in the Company's ADSs effective with the opening of business on Friday, April 26, 2024, and file a Form 25 with the Securities and Exchange Commission (the "SEC") to effect the formal delisting of the Company's ADSs from The Nasdaq Capital Market once all applicable Nasdaq appeal and review periods have expired.

PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / April 19, 2024 / Biophytis SA (Nasdaq CM:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio of its American Depositary Shares (the "ADSs") to Biophytis ordinary shares (the "Shares") from one ADS representing 100 Shares, to one ADS representing 4,000 Shares (the "Ratio Change"). The effective date of the Ratio Change (the "Effective Date") is expected to be April 23, 2024.

IND to be filed with the FDA in the coming weeks PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 18, 2024 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, today announces the formation of a new Scientific Advisory Board to support the advancement of its phase 2 OBA clinical study in obesity. This Scientific Advisory Board will be composed of a few worldwide medical experts in the field of obesity, including Professor Dennis Villareal from the USA and Professor Francisco Guarner from Spain.

Biophytis (BPTS) rises in the after-market hours as it announces the launch of a new clinical development program for its investigational candidate, BIO101, to treat obesity in combination with GLP-1 drugs.

Biophytis (NASDAQ: BPTS ) stock is rocketing higher on Tuesday after releasing its earnings results for the full year of 2023. Biophytis  is still a clinical-stage biotechnology, which means it had no revenue to report for 2023.

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 8, 2024 / Biophytis SA (NASDAQ:BPTS), (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, publishes today its financial results for the year ended December 31, 2023, and provides an update on the progress of its various programmes. "In 2023, despite a particularly difficult financial environment for the biotech sector, we succeeded in pursuing the development of our clinical programmes, while securing the company's financing until early 2025," states Stanislas Veillet, CEO of Biophytis.

Promising preclinical results obtained in obesity support the OBA Phase 2 clinical study expected to start mid-2024 PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / April 8, 2024 / Biophytis SA (Nasdaq:BPTS)(Euronext Growth Paris: ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, today announces that it is launching a new clinical development program named OBA, with BIO101 (20-hydroxyecdysone) as a potential treatment for obesity in combination with GLP-1 receptor agonists. Muscle loss due to obesity treatment: no therapy available today Obesity treatment can lead to loss of muscle mass and function, notably as a consequence of dieting when combined with the recently introduced GLP-1 receptor agonists.

All resolutions presented by the Company have been adopted PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / April 4, 2024 / Biophytis SA (NASDAQ:BPTS),(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, announces the approval of all the resolutions presented by the Company and falling within the remit of the Ordinary and Extraordinary General Meeting. Thanks to the mobilization of shareholders, the Meeting could be held with a quorum of almost 30% of the shareholders present or represented.

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / March 22, 2024 / Biophytis SA (Nasdaq:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, presented its phase 3 protocol aimed at demonstrating the potential of RuvembriTM (20-hydroxyecdysone) in the treatment of sarcopenia at the International Conference on Frailty and Sarcopenia Research (ICFSR), held from March 20 to 22, 2024 in Albuquerque, NM, USA. The SARA-INT phase 2 study showed promising results on physical performance, with significant improvement in the 400 Meter Walking Test, reaching 0.07 m/s in the Full Analysis Set population and 0.09 m/s in the Per Protocol population.

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / November 17, 2023 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related neuromuscular and respiratory diseases, today announced that it has received written notification (the "Notification Letter") from the Nasdaq Stock Market LLC ("Nasdaq") dated November 15, 2023, indicating that, based upon a closing bid price of less than $1.00 per share for the Company's American Depositary Shares ("ADSs") for the prior 30 consecutive business days period, the Company no longer satisfies Nasdaq Listing Rule 5550(a)(2). The Notification Letter has no immediate effect on the listing of the ADSs, and they will continue to trade on The Nasdaq Global Select Market under the symbol "BPTS".